Brimonidine

DEA Class; Rx, OTC

Common Brand Names; Alphagan P, Qoliana, Lumify, Mirvaso

• Antiglaucoma, Alpha Agonists
• Acne Agents, Topical; 
• Alpha Agonists, Topical

Selective alpha-2 adrenergic agonist
Used ophthalmically to reduce intraocular pressure in open-angle glaucoma and ocular hypertension and to relieve ocular redness due to irritation and topically to reduce persistent facial erythema of rosacea
Minimal cardiopulmonary effects

Indicated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

Indicated to relieve ocular redness caused by minor eye irritations

Treatment of anterior ischemic optic neuropathy

Indicated for persistent facial erythema of rosacea

Hypersensitivity to product or components

Children <2 years (0.1-0.15% ophthalmic solution)

• Oral dryness
• Conjunctival hyperemia
• Allergic conjunctivitis
• Eye pruritus
• Rash
• Photophobia
• Headache
• Fatigue
• Dizziness
• Dyspepsia
• Blepharitis
• Eye discharge

Remove contact lenses before instilling eye drops; wait 15 min before reinserting contact lenses

If >1 ophthalmic product is being administered, wait 5 minutes between instilling eye drops

May potentiate syndromes associated with vascular insufficiency; caution with depression, cerebral or coronary insufficiency, Raynaud phenomenon, orthostatic hypotension, or thromboangiitis obliterans

Although brimonidine ophthalmic had minimal effect on the blood pressure of patients in clinical studies, caution with severe cardiovascular disease

Bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products; instruct patients on how to avoid contamination

Pregnancy Category: B

Lactation: It is not known whether this drug is excreted in milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Do not apply to more than 100 cm2 in total area.

Do not apply to more than 100 cm2 in total area.

Do not apply to more than 2% total body surface area.

Do not apply to more than 2% total body surface area.

9 to 11 months: Do not apply to more than 2% total body surface area.
1 to 9 months: Safety and efficacy have not been established.

Safety and efficacy have not been established.

Brimonidine tartrate

ophthalmic solution (Rx)

• 0.1% (Alphagan P)
• 0.15% (Alphagan P, Qoliana, generic)

ophthalmic solution (OTC)

• 0.025% (Lumify)

topical gel

• 0.33%